Boston Scientific launches next-gen pacemaker lead trial

Mon, 12/17/2012 - 12:49pm
Mass Device

Boston Scientific says the 1st patient is implanted with its next-generation Ingevity MRI-safe pacemaker leads.

Boston Scientific

Boston Scientific (NYSE:BSX) said it's begun a clinical trial of its Ingevity next-generation pacemaker leads, designed to be safe for MRI procedures.

The Marlborough, Mass.-based medical device company said a patient in Sweden was the first enrollee in the trial, which is aimed at proving the safety and effectiveness of the devices in treating slow heartbeats or bradycardia.

The new leads are likely to be paired with Boston Scientific's Ingenio pacemaker line, according to a press release. The company is hoping the data from the 1,000-patient trial will back regulatory nods in the U.S. and the European Union, according to the release.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.